Evidence map›Paper›PMID 40300713›Full record

ArticleContemporary clinical trials2025

Rationale and design of a randomized controlled trial evaluating the effects of blueberry consumption versus placebo on brain health in older adults.

Zachary Uttke, Olivia Gabriel, Ceilidh Smith, Eric T Guardino, Kenneth Mukamal, Luc Djousse

Abstract readClinical Trial Protocol
In one paragraph

Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zachary UttkeGreater Boston Medical Student Aging Research, Boston, MA, USA; MD/PhD Program, Brown University, Providence, RI, USA; STX-MSTP, University of Texas Health San Antonio, San Antonio, TX, USA.
Olivia GabrielBrigham and Women's Hospital, Boston, MA, USA.
Ceilidh SmithBrigham and Women's Hospital, Boston, MA, USA.
Eric T GuardinoBrigham and Women's Hospital, Boston, MA, USA.
Kenneth MukamalBeth Israel Deaconess Medical Center, Boston, MA, USA; Harvard Medical School and Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Luc DjousseGreater Boston Medical Student Aging Research, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School and Harvard T. H. Chan School of Public Health, Boston, MA, USA. Electronic address: ldjousse@bwh.harvard.edu.

Funding

Greater Boston Medical Student Training in Aging ResearchT35AG038027 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI DRIVER, JANE A, MCLAUGHLIN-GAVIN, CARA · 2010 to 2024
$991k
NIA NIH HHS T35 AG038027
6 · The paper itself

Abstract

backgroundAge-related cognitive decline results in significant clinical and public health costs. Cognitive decline predisposes individuals to dementia and leads to difficulties with activities of daily living and increased hospitalizations. While a few dietary interventions have shown considerable promise at delaying cognitive decline, studies of the effects of long-term blueberry consumption on brain health among older adults have been limited and equivocal.

objectiveTo test the hypothesis that a 24-week intervention with blueberry powder versus placebo will improve (i) plasma biomarkers of brain health and (ii) cognitive performance in older adults.

methodsThis randomized, double-blind, placebo-controlled trial will be conducted in older Americans aged 65-99 years old. Sixty-seven participants will be randomly assigned to receive either blueberry powder (20 g/d - equivalent of one (1) cup of fresh blueberries) or a placebo powder (20 g/d) for 24 weeks. Participants will undergo four clinic visits (baseline and 8 weeks, 16 weeks, and 24 weeks after randomization) for cognitive assessments, blood pressure measurements, and blood sample collections. Primary outcomes will be plasma levels of neurofilament light chain (NFL) and phosphorylated tau protein (pTau-181). Secondary outcomes will be plasma levels of glial fibrillary acidic protein (GFAP) and non-esterified fatty acids (NEFA); blood pressure during visits; and cognitive function.

conclusionFindings from this trial will answer the question whether a long-term intervention with blueberry powder can improve (i) plasma biomarkers of brain health and (ii) cognitive function in older adults.

Indexed as

Blueberry PlantsCognitionCognitive DysfunctionAgedAged, 80 and overBiomarkersBlood PressureBrainDouble-Blind MethodFemaleHumansMaleNeurofilament ProteinsRandomized Controlled Trials as TopicBiomarkersNeurofilament ProteinsBiomarkersBlueberriesClinical trialCognitive functionOlder adults

Identifiers

PMID40300713
PMCPMC12145229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.